down arrow

Affimed NV

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: NL0010872420
USD
0.00
0.00 (0.00%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.002.82
Valuation
Technical
Day's Volume

CASH

5.95 k

Shareholding (Sep 2024)

FII

3.86%

Held by 34 FIIs

DII

83.85%

Held by 9 DIIs

Promoter

4.09%

How big is Affimed NV?

22-Jun-2025

As of Jun 18, Affimed NV has a market capitalization of 1.26 million, with net sales of 0.95 million and a net profit of -75.80 million over the last four quarters. The company reported shareholder's funds of 63.86 million and total assets of 107.32 million as of Dec 23.

Market Cap: As of Jun 18, Affimed NV has a market capitalization of 1.26 million, categorizing it as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Affimed NV reported net sales of 0.95 million and a net profit of -75.80 million.<BR><BR>Balance Sheet Snapshot: As of Dec 23, the company reported shareholder's funds of 63.86 million and total assets of 107.32 million.

Read More

What does Affimed NV do?

22-Jun-2025

Affimed N.V. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies, currently reporting no net sales and a net loss of $17 million as of September 2024, with a market cap of $1.26 million. The company has a negative return on equity and does not pay dividends.

Overview:<BR>Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Sep 2024) <BR>Most recent Net Profit: -17 Million (Quarterly Results - Sep 2024) <BR>Market cap: USD 1.26 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.87 <BR>Return on Equity: -395.01% <BR>Price to Book: 0.07<BR><BR>Contact Details:<BR>Address: Im Neuenheimer Feld 582, HEIDELBERG None: 69120 <BR>Tel: 49 6221 65307 <BR>Fax: 49 6221 6743649 <BR>Website: https://www.affimed.com/

Read More

Who are in the management team of Affimed NV?

22-Jun-2025

As of March 2022, the management team of Affimed NV includes Dr. Thomas Hecht (Chairman) and five independent members: Dr. Bernhard Ehmer, Dr. Ulrich Grau, Mr. Berndt Modig, Dr. Mathieu Simon, and Dr. Ferdinand Verdonck, who oversee the company's strategic direction and governance.

As of March 2022, the management team of Affimed NV includes the following members of the Board of Directors:<BR><BR>- Dr. Thomas Hecht: Independent Chairman of the Supervisory Board<BR>- Dr. Bernhard Ehmer: Independent Member of the Supervisory Board<BR>- Dr. Ulrich Grau: Independent Member of the Supervisory Board<BR>- Mr. Berndt Modig: Independent Member of the Supervisory Board<BR>- Dr. Mathieu Simon: Independent Member of the Supervisory Board<BR>- Dr. Ferdinand Verdonck: Independent Member of the Supervisory Board<BR><BR>This team is responsible for overseeing the company's strategic direction and governance.

Read More

Is Affimed NV technically bullish or bearish?

25-Jun-2025

As of June 4, 2025, Affimed NV's trend is mildly bearish, with mixed signals from moving averages, MACD, and RSI, indicating a lack of strong conviction in either direction.

As of 4 June 2025, the technical trend for Affimed NV has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating bearish momentum, while the weekly MACD and RSI show mildly bullish and bullish signals respectively. However, the Bollinger Bands and KST on a weekly basis remain bearish, suggesting underlying weakness. The Dow Theory indicates no trend in both weekly and monthly time frames, further supporting a neutral outlook. Overall, the mixed signals reflect a lack of strong conviction in either direction.

Read More

Is Affimed NV overvalued or undervalued?

25-Jun-2025

As of November 14, 2024, Affimed NV is considered overvalued with a valuation grade of "does not qualify," reflecting significant financial challenges, including a -395.01% return on equity and a 98.47% stock decline over the past year, underperforming the S&P 500's 10.26% return.

As of 14 November 2024, Affimed NV's valuation grade has moved from risky to does not qualify, indicating a significant deterioration in its financial health. The company is currently considered overvalued given its negative financial metrics, including a price-to-book value of 0.05 and an EV to EBITDA ratio of 0.21. The return on equity stands at a staggering -395.01%, highlighting the challenges the company faces in generating profits.<BR><BR>When compared to peers, Affimed NV's valuation appears unfavorable. For instance, Kodiak Sciences, Inc. also does not qualify but has a more manageable EV to EBITDA ratio of -0.9313, while Compugen Ltd. is rated risky with an EV to EBITDA of -3.4456. The stark contrast in these ratios suggests that Affimed NV is not only struggling but is also overvalued relative to its peers. Additionally, the company's stock has plummeted 98.47% over the past year, significantly underperforming the S&P 500, which returned 10.26% in the same period.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.87

stock-summary
Return on Equity

-395.01%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Sep 2024)
Net Profit:
-17 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
-99.69%
0%
-99.69%
1 Year
-100.0%
0%
-100.0%
2 Years
-100.0%
0%
-100.0%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

Affimed NV for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-53.91%
EBIT Growth (5y)
-227.74%
EBIT to Interest (avg)
-55.98
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.87
Sales to Capital Employed (avg)
0.16
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
49.28%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.05
EV to EBIT
0.20
EV to EBITDA
0.21
EV to Capital Employed
-6.30
EV to Sales
-15.67
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-395.01%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Bearish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 28 Schemes (8.2%)

Foreign Institutions

Held by 34 Foreign Institutions (3.86%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is 0.00% vs 20.19% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.20",
          "val2": "-16.30",
          "chgp": "6.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.60",
          "val2": "-16.60",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-92,206.50%",
          "val2": "-101,357.10%",
          "chgp": "915.06%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -79.54% vs -8.81% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -26.66% vs -32.94% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.90",
          "val2": "43.50",
          "chgp": "-79.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-118.50",
          "val2": "-91.10",
          "chgp": "-30.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "1.70",
          "chgp": "17.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-114.50",
          "val2": "-90.40",
          "chgp": "-26.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-13,457.20%",
          "val2": "-2,165.20%",
          "chgp": "-1,129.20%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQstock-summary
Sep'24
Jun'24
Change(%)
Net Sales
0.20
0.20
Operating Profit (PBDIT) excl Other Income
-15.20
-16.30
6.75%
Interest
0.30
0.30
Exceptional Items
0.00
0.00
Consolidate Net Profit
-16.60
-16.60
Operating Profit Margin (Excl OI)
-92,206.50%
-101,357.10%
915.06%
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Sep 2024 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2024 is 0.00% vs 20.19% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
8.90
43.50
-79.54%
Operating Profit (PBDIT) excl Other Income
-118.50
-91.10
-30.08%
Interest
2.00
1.70
17.65%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-114.50
-90.40
-26.66%
Operating Profit Margin (Excl OI)
-13,457.20%
-2,165.20%
-1,129.20%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is -79.54% vs -8.81% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -26.66% vs -32.94% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About Affimed NV stock-summary
stock-summary
Affimed NV
Pharmaceuticals & Biotechnology
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Company Coordinates stock-summary
Company Details
Im Neuenheimer Feld 582 , HEIDELBERG None : 69120
stock-summary
Tel: 49 6221 65307
stock-summary
https://www.affimed.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."